Company Legal Name
Latest Valuation
Founded Year
Headquarter
Chai Discovery develops artificial intelligence tools for predicting biomolecular structures and designing de novo therapeutic antibodies. Based in San Francisco, the company leverages advanced computational methods to accelerate drug discovery processes, offering pharmaceutical companies and research institutions enhanced capabilities for protein structure prediction and antibody engineering. Their AI-driven platform addresses critical bottlenecks in therapeutic development by providing accurate molecular modeling and novel antibody design solutions. With the global antibody therapeutics market experiencing rapid growth and increasing demand for computational drug discovery tools, Chai Discovery is positioned to capitalize on the convergence of artificial intelligence and biotechnology innovation.
Revenue & Revenue Growth Share
Revenue
Revenue Growth
Available in most regions; subject to local regulations.
Open to non-accredited investors with KYC/AML compliance. U.S. investors must meet SEC requirements.
$10 per token, enabling fractionalized access to Pre-IPO shares.
Mandatory identity (KYC) and proof of funds checks.
Variable, applied to investment amounts.
Charged on realized profits.
Tokens may be locked for 6–12 months; resale depends on secondary market liquidity.
Prices reflect past funding rounds, not guaranteed future value.
Biotech depends on regulatory approvals; fintech faces evolving digital asset rules.
Blockchain or custodian issues could delay transfers or verification.
Changing laws may affect tradability or taxation.
